Case Based Panel Discussion 2.7 Clinical Significance of HER2 Mutation How Does a Positive HER2 Mutation Effect Treatment Decisions in NSCLC episode artwork

EPISODE · May 6, 2020 · 7 MIN

Case Based Panel Discussion 2.7 Clinical Significance of HER2 Mutation How Does a Positive HER2 Mutation Effect Treatment Decisions in NSCLC

from GRACEcast - Discussions with the Global Resource for Advancing Cancer Education · host cancerGRACE

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.The doctors discuss a series of cases related to a diagnosis of NSCLC. In this video, the discussion is regarding a patient with a HER2 mutation, what is the clinical significance, and how does a positive HER2 mutation effect treatment decisions?

Episode metadata supplied by the publisher feed · Published May 6, 2020

Embed this episode

NOW PLAYING

Case Based Panel Discussion 2.7 Clinical Significance of HER2 Mutation How Does a Positive HER2 Mutation Effect Treatment Decisions in NSCLC

0:00 7:19

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of GRACEcast - Discussions with the Global Resource for Advancing Cancer Education?

This episode is 7 minutes long.

When was this GRACEcast - Discussions with the Global Resource for Advancing Cancer Education episode published?

This episode was published on May 6, 2020.

Can I download this GRACEcast - Discussions with the Global Resource for Advancing Cancer Education episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!